Loading...
Market
What will be the outcome of the next major clinical trial for mpox treatment by end of 2024?
2
Resolution / Starting Odds
Significant improvement in lesion resolution • 25%
No improvement in lesion resolution • 25%
Worsening of lesion resolution • 25%
Trial inconclusive • 25%
NIAID official reports or peer-reviewed publication
Story
Tecovirimat Fails in PALM007 Trial for Mpox Lesion Resolution in DRC
Aug 15, 2024, 12:09 PM
The National Institute of Allergy and Infectious Diseases (NIAID) has reported that the antiviral drug tecovirimat did not demonstrate a statistically significant improvement in resolving mpox lesions within 28 days in the PALM007 trial. This trial, conducted in the Democratic Republic of the Congo, focused on clade I of the mpox virus, which is known for causing more severe disease. The initial analysis showed no reduction in lesion duration among children and adults. These findings are particularly concerning following the World Health Organization's recent declaration of mpox as a public health emergency of international concern, as the more pathogenic clade 1b spreads rapidly in Africa.
View original story
Similar markets
Vaccine • 25%
Antiviral treatment • 25%
Both • 25%
Neither • 25%
Effective • 25%
Moderately Effective • 25%
Ineffective • 25%
Halted • 25%
Successful with no major side effects • 25%
Successful with some side effects • 25%
Unsuccessful • 25%
Inconclusive • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
